Case Study: IsoPSA Reveals csPCa in a PI-RADS 2 Lesion
Автор: IsoPSA
Загружено: 2025-05-23
Просмотров: 162
While evaluating a patient with elevated PSA and a PI-RADS 2 lesion, Dr. Arpeet Shah,
board-certified urologist at Associated Urological Specialists, noted the patient had an
elevated IsoPSA Index. Based on this result, he proceeded with a biopsy, which revealed
prostate cancer with a Gleason score of 8.
This material concerns IsoPSA, a laboratory developed test from Cleveland Diagnostics, Inc., which is regulated under CLIA and qualified to perform high complexity clinical testing. As an LDT, IsoPSA has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: